Results 81 to 90 of about 5,866 (194)

Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry:A Cross-sectional Study of Common Conditions in the United States [PDF]

, 2013
BACKGROUND: Financial ties between health professionals and industry may unduly influence professional judgments and some researchers have suggested that widening disease definitions may be one driver of over-diagnosis, bringing potentially unnecessary ...
Bero, Lisa, Cooke, Georga P E, Doust, Jenny A., Glasziou, Paul P., Hill, Suzanne, Moynihan, Raymond N.   +5 more
core   +4 more sources

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors

British Journal of Pharmacology, Volume 182, Issue S1, Page S259-S306, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Chloe J. Peach, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Laura Kilpatrick, Doris Koesling, Michaela Kuhn, Birgit Leitinger, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +31 more
wiley   +1 more source

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis: systematic review and mixed method treatment comparison [PDF]

Background This study assesses the efficacy of three granulocyte colony-stimulating factors (G-CSFs; pegfilgrastim, filgrastim and lenograstim) in preventing febrile neutropenia (FN). Methods A systematic review was undertaken.
Akehurst, R., Cooper, K.L., Madan, J., Stevenson, M.D., Whyte, S.   +4 more
core  

Nanomedicines for the delivery of biologics [PDF]

, 2019
A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs.
Desai, Arpan, Greco, Francesca, Hill, Kathryn, Jones, Arwyn T., Mrsny, Randall J., Pasut, Gianfranco, Perrie, Yvonne, Seib, F. Philipp, Seymour, Leonard W., Uchegbu, Ijeoma F., Wahlich, John   +10 more
core   +6 more sources

Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom [PDF]

Introduction: We report a cost-effectiveness evaluation of granulocyte colony–stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) after chemotherapy in the United Kingdom (UK).
Akehurst, R, Cooper, KL, Madan, J, Stevenson, MD, Whyte, S   +4 more
core  

Use of granulocyte growth factors: recommendations of the Portuguese Society of Hematology [PDF]

, 2008
The administration of cytotoxic chemotherapy may be complicated by the emergence of neutropenia and febrile neutropenia, frequently determining hospital admission and intravenous treatment with broad spectrum antibiotics.
Forjaz de Lacerda, J, Leal da Costa, F, Parreira, A, Pereira, AM, Principe, F, Teixeira, A   +5 more
core  

Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy

Haematologica, 2008
Quality and quantity of mobilized peripheral blood stem cells determine the safety of tandem autologous transplants in myeloma. Using the same mobilization chemotherapy with DT-PACE in two consecutive protocols, robustness of stem cell collection and ...
Guido Tricot, Bart Barlogie, Maurizio Zangari, Frits van Rhee, Antje Hoering, Jackie Szymonifka, Michele Cottler-Fox   +6 more
doaj   +1 more source

Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study

Journal of Cartilage & Joint Preservation
Introduction: Hematopoietic stem cells (HSCs) appear in peripheral blood (PB) following mobilization due to external events or pharmaceutical agents like filgrastim and pegfilgrastim.
Mohammadreza Abbasian, Eric Branch, Ali Parsa, Jessica Truett, Joshua J. Cook, Charlkesha A. Rahming, Adam W. Anz   +6 more
doaj   +1 more source

Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma

British Journal of Haematology, Volume 208, Issue 1, Page 308-311, January 2026.
Max J. Gordon, Rahul Lakhotia, Stefania Pittaluga, Svetlana D. Pack, Anna Marie Juanitez, Ahmed Hamdy, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Mark Raffeld, Mark Roschewski, Wyndham H. Wilson, Christopher Melani   +12 more
wiley   +1 more source

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial

Pharmacology Research & Perspectives, 2020
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®.
Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl   +8 more
doaj   +1 more source